SEC 13F Intelligence

Octagon Capital Advisors LP / APLSUSD

Octagon Capital Advisors LP’s Apellis Pharmaceuticals Inc Position

Does Octagon Capital Advisors LP own Apellis Pharmaceuticals Inc (APLSUSD)? Not currently — the last reported position was 903.5K shares worth $20M in Q3 2025; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$20M
Q3 2025
Shares
903.5K
% of Portfolio
+3.10%
Quarters Held
20
position exited

Position History APLSUSD

Reported value by quarter
Q4 ’20: $31MQ4 ’20Q1 ’21: $24MQ2 ’21: $79MQ3 ’21: $53MQ3 ’21Q4 ’21: $96MQ1 ’22: $119MQ2 ’22: $117MQ2 ’22Q3 ’22: $171MQ4 ’22: $163MQ1 ’23: $214MQ1 ’23Q2 ’23: $239MQ3 ’23: $119MQ4 ’23: $168MQ4 ’23Q1 ’24: $165MQ2 ’24: $111MQ3 ’24: $87MQ3 ’24Q4 ’24: $96MQ1 ’25: $46MQ2 ’25: $16MQ2 ’25Q3 ’25: $20Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q3 2025903.5K$20M+3.10%
Q2 2025903.5K$16M+3.43%
Q1 20252.09M$46M+8.86%
Q4 20243.01M$96M+15.79%
Q3 20243.01M$87M+13.49%
Q2 20242.88M$111M+17.37%
Q1 20242.81M$165M+19.77%
Q4 20232.81M$168M+26.88%
Q3 20233.13M$119M+18.29%
Q2 20232.62M$239M+33.19%
Q1 20233.25M$214M+30.84%
Q4 20223.16M$163M+25.44%
Q3 20222.50M$171M+29.50%
Q2 20222.58M$117M+31.17%
Q1 20222.34M$119M+25.70%
Q4 20212.02M$96M+18.59%
Q3 20211.60M$53M+12.95%
Q2 20211.26M$79M+16.44%
Q1 2021548.4K$24M+8.86%
Q4 2020548.4K$31M+10.87%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Octagon Capital Advisors LP’s full portfolio or all institutional holders of APLSUSD.